The Sleep Disorders
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
ON ATTRACTION of SLIME MOULD PHYSARUM POLYCEPHALUM to PLANTS with SEDATIVE PROPERTIES 1. Introduction Physarum Polycephalum Belo
ON ATTRACTION OF SLIME MOULD PHYSARUM POLYCEPHALUM TO PLANTS WITH SEDATIVE PROPERTIES ANDREW ADAMATZKY Abstract. A plasmodium of acellular slime mould Physarum polycephalum is a large single cell with many nuclei. Presented to a configuration of attracting and repelling stimuli a plasmodium optimizes its growth pattern and spans the attractants, while avoiding repellents, with efficient network of protoplasmic tubes. Such behaviour is interpreted as computation and the plasmodium as an amorphous growing biologi- cal computer. Till recently laboratory prototypes of slime mould computing devices (Physarum machines) employed rolled oats and oat powder to represent input data. We explore alternative sources of chemo-attractants, which do not require a sophis- ticated laboratory synthesis. We show that plasmodium of P. polycephalum prefers sedative herbal tablets and dried plants to oat flakes and honey. In laboratory experi- ments we develop a hierarchy of slime-moulds chemo-tactic preferences. We show that Valerian root (Valeriana officinalis) is strongest chemo-attractant of P. polycephalum outperforming not only most common plants with sedative activities but also some herbal tablets. Keywords: Physarum polycephalum, slime mould, valerian, passion flower, hops, ver- vain, gentian, wild lettuce, chemo-attraction 1. Introduction Physarum polycephalum belongs to the species of order Physarales, subclass Myxo- gastromycetidae, class Myxomycetes, division Myxostelida. It is commonly known as a true, acellular or multi-headed slime mould. Plasmodium is a `vegetative' phase, single cell with a myriad of diploid nuclei. The plasmodium looks like an amorphous yellowish mass with networks of protoplasmic tubes. The plasmodium behaves and moves as a giant amoeba. It feeds on bacteria, spores and other microbial creatures and micro- particles (Stephenson & Stempen, 2000). -
Yerevan State Medical University After M. Heratsi
YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule. -
2020 Question Book
2020 QUESTION BOOK 13TH EDITION WHO WE ARE Welcome to the thirteenth edition of the Ninja’s Guide to PRITE! Loma Linda University Medical Center is located in sunny Southern California. about 60 miles east of Los Angeles. A part of the Adventist Health System, we provide patient care in one of the largest non-profit health systems in the nation. Loma Linda's mission is to excel in medical education, global healthcare, and community outreach, all under a central tenant: "To Make Man Whole." At the Loma Linda Department of Psychiatry, our residents are trained in many diverse patient care settings. As an official World Health Organization Collaboration Center, our department funds resident electives in Global Mental Health at locations around the world. Additionally, our residents can participate in national and international disaster relief on the LLU Behavioral Health Trauma Team. We were proud to welcome our first group of Child and Adolescent Psychiatry fellows in the Summer of 2019 and work collaboratively with 3 other residency programs within the region. Our residency didactic education is constantly evolving based upon resident feedback, and our residents have the opportunity to aid in course development. More than anything, our residency fosters an environment where residents and faculty treat each other like family. Our faculty are dedicated to resident education and professional development. We believe in "taking 'No' off the table", encouraging innovative change, and passionately supporting our residents to achieve anything they set their minds to. For over a decade our residents have volunteered their time to create The Ninja's Guide to PRITE at our Annual Ninja PRITE Workshop. -
The Everyday Lives of Recovering Heroin Users
The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering The everyday lives of recovering heroin users The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering Joanne Neale Professor of Public Health Faculty of Health & Life Sciences Oxford Brookes University Jack Straw’s Lane Marston Oxford OX3 0FL Email: [email protected] Sarah Nettleton Reader in Sociology Department of Sociology Wentworth College University of York Heslington York YO10 5DD Email: [email protected] Lucy Pickering Lecturer in Anthropology School of Social and Political Sciences University of Glasgow Adam Smith Building Glasgow G12 8RT Email: [email protected] Published by the RSA 8 John Adam Street London WC2N 6EZ +44 (0)20 7930 5115 Registered as a charity in England and Wales no. 212424 and in Scotland no. SCO 37784 Copyright © Joanne Neale 2012 The RSA is an enlightenment organisation devoted to finding innovative and practical solutions to today’s pressing social problems Cover photo: ‘Wings of butterfly,’ John Foxx. © Thinkstock Designed by Soapbox, www.soapbox.co.uk Printed and bound by CPI Antony Rowe www.theRSA.org Contents Acknowledgements 9 Foreword 10 Chapter 1: Setting the scene 14 Why read this book? 14 Why focus on recovery? 15 What is recovery? 15 A study of the everyday lives of recovering heroin users 17 Structure of the book 18 Chapter 2: Considering recovery 20 Introduction 20 Mapping services and support 20 Factors that can encourage and sustain recovery efforts -
Receives Fda Approval for the Treatment of Insomnia
AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED-RELEASE TABLETS) CIV RECEIVES FDA APPROVAL FOR THE TREATMENT OF INSOMNIA First and Only Extended-Release Prescription Sleep Medication Indicated for Sleep Induction and Maintenance Covers Broad Insomnia Population Paris, France, September 6, 2005 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number ® one prescription sleep aid, AMBIEN (zolpidem tartrate) CIV, for the treatment of insomnia. AMBIEN CR is non-narcotic and a non-benzodiazepine, formulated to offer a similar safety profile to AMBIEN with a new indication for sleep maintenance, in addition to sleep induction. AMBIEN CR is the first and only extended-release prescription sleep medication to help people with insomnia fall asleep fast and maintain sleep with no significant decrease in next day performance. AMBIEN CR, a bi-layered tablet, is delivered in two stages. The first layer dissolves quickly to induce sleep. The second layer is released more gradually into the body to help provide more continuous sleep. “Insomnia is a significant public health problem, affecting millions of Americans. Insomnia impacts daily activities and is associated with increased health care costs,” said James K. Walsh, PhD, Executive Director and Senior Scientist, Sleep Medicine and Research Center at St. Luke's Hospital in St. Louis, Missouri. “Helping patients stay asleep is recognized as being as important as helping them fall asleep,” said Walsh. “Ambien CR has shown evidence of promoting sleep onset and more continuous sleep". -
In This Section
Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group. -
Sleep Problems
Sleep Problems About 70 million Americans have some kind of sleep problem, and for many it’s a long-term problem. Even though sleep problems are very common, they are very often undiagnosed and untreated. Here are descriptions of some of the most common sleep problems. Bruxism Bruxism is grinding, gnashing, or clenching your teeth during sleep or in situations that make you feel anxious or tense. It can be mild and happen only once in a while, or it may be violent and happen often. Bruxism most often happens in the early part of the night. You may not be aware that you have bruxism until your teeth or jaws are damaged. People who have bruxism are also more likely to snore and develop sleep apnea. Hypersomnia Hypersomnia is excessive daytime sleepiness or prolonged nighttime sleep. If you have hypersomnia, you feel very drowsy during the day and have an overwhelming urge to fall asleep, even after getting enough sleep at night. You often doze, nap, or fall asleep in situations where you need or want to be awake and alert. Other symptoms may include irritability, mild depression, trouble concentrating, and memory loss. Kleine-Levin Syndrome Kleine-Levin syndrome is a rare disorder that causes you to be extremely drowsy off and on. You may sleep up to 20 hours a day. Other symptoms include eating too much, being irritable, feeling disoriented, lacking energy, and being very sensitive to noise. The disorder usually starts in the late teens and is more common in men than in women. Symptoms may last for days to weeks, then go away, and then come back. -
Nightmares and Bad Dreams in Patients with Borderline Personality Disorder: Fantasy As a Coping Skill?
Eur. J. Psychiat. Vol. 24, N.° 1, (28-37) 2010 Keywords: Borderline Personality Disorder; Night- mares; Affect regulation; Fantasy. Nightmares and bad dreams in patients with borderline personality disorder: Fantasy as a coping skill? Peter Simor*,** Szilvia Csóka*** Róbert Bódizs***,**** * Implicit Laboratory Association, Budapest ** Department of Cognitive Sciences, Budapest University of Technology and Economics, Budapest *** Institute of Behavioural Sciences, Semmelweis University, Budapest **** HAS-BME Cognitive Science Research Group, Hungarian Academy of Sciences, Budapest HUNGARY ABSTRACT – Background and Objectives: Previous studies reported a high prevalence of nightmares and dream anxiety in Borderline Personality Disorder (BPD) and the sever- ity of dream disturbances correlated with daytime symptoms of psychopathology. Howev- er, the majority of these results are based on retrospective questionnaire-based study de- signs, and hence the effect of recall biases (characteristic for BPD), could not be controlled. Therefore our aim was to replicate these findings using dream logs. Moreover, we aimed to examine the level of dream disturbances in connection with measures of emo- tional instability, and to explore the protective factors against dream disturbances. Methods: 23 subjects diagnosed with BPD, and 23 age and gender matched healthy controls were assessed using the Dream Quality Questionnaire, the Van Dream Anxiety Scale, as well as the Neuroticism, Assertiveness and Fantasy scales of the NEO-PI-R ques- tionnaire. Additionally, subjects were asked to collect 5 dreams in the three-week study period and to rate the emotional and phenomenological qualities of the reported dreams using the categories of the Dream Quality Questionnaire. Results: Dream disturbances (nightmares, bad dreams, night terror-like symptoms, and dream anxiety) were more frequent in patients with BPD than in controls. -
The ICD-10 Classification of Mental and Behavioural Disorders : Clinical Descriptions and Diagnostic Guidelines
ICD-10 ThelCD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines | World Health Organization I Geneva I 1992 Reprinted 1993, 1994, 1995, 1998, 2000, 2002, 2004 WHO Library Cataloguing in Publication Data The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. 1.Mental disorders — classification 2.Mental disorders — diagnosis ISBN 92 4 154422 8 (NLM Classification: WM 15) © World Health Organization 1992 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Sleep Parameters During Polysomnography and Continuous Positive Airway Pressure Titration in Severe Obstructive Sleep Apnea Adult Patients
ISSN: 2455-1759 DOI: https://dx.doi.org/10.17352/aor CLINICAL GROUP Received: 30 June, 2021 Research Article Accepted: 24 July, 2021 Published: 26 July, 2021 *Corresponding author: Utku Kubilay, MD, Sleep parameters during Department of Otorhinolaryngology, Ekol Hospital, Istanbul, 8211/11 Sk.No:4 Daire 8, Izmir/Cigli, Turkey, Tel: +90 536 844 86 52; polysomnography and E- mail: Keywords: Obstructive sleep apnea syndrome; continuous positive airway Continuous positive airway pressure; REM sleep; REM density pressure titration in severe https://www.peertechzpublications.com obstructive sleep apnea adult patients Utku Kubilay* Department of Otorhinolaryngology, Ekol Hospital, Istanbul, Turkey Abstract Objectives: The aim of the present study was to demonstrate the effect of continuous positive airway pressure treatment on sleep parameters in severe obstructive sleep apnea patients. Patients/methods: Data regarding apnea-hypopnea index, total sleep time, sleep effi ciency, rapid-eye-movement (REM) density, REM latency, total REM episodes during polysomnography and continuous positive airway pressure titration according to the obstructive sleep apnea severity were compared. Results: Of the 51 patients whose charts were reviewed, the average age was 46.47±10.62 years and the mean body mass index was 31.71±4.97 kg/m2. Thirty-two patients who had an apnea-hypopnea index between 30 and 60/h included to the Group 1 and 19 patients who had an apnea-hypopnea index ≥60/h included to the Group 2. Among all studied parameters, only rapid-eye-movement latency showed statistical signifi cance between the studied groups. Changes in rapid-eye-movement latency differed signifi cantly among patients during polysomnography and continuous positive airway pressure titration in Group 2 (p=0.003). -
Early-Onset Parkinson's Disease Caused by PLA2G6 Compound
CASE REPORT published: 21 August 2019 doi: 10.3389/fneur.2019.00915 Early-Onset Parkinson’s Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review Ting Shen 1,2,3, Jing Hu 1,2, Yasi Jiang 2,3, Shuai Zhao 1,2, Caixiu Lin 1,2, Xinzhen Yin 1,2, Yaping Yan 1,2, Jiali Pu 1,2, Hsin-Yi Lai 2,3* and Baorong Zhang 1,2* 1 Department of Neurology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China, 2 Department of Neurology of the Second Affiliated Hospital, Interdisciplinary Institute of Neuroscience and Technology, Zhejiang University School of Medicine, Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University, Hangzhou, China, 3 Key Laboratory of Biomedical Engineering of Ministry of Education, Qiushi Academy for Edited by: Advanced Studies, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, China Ruey-Meei Wu, National Taiwan University, Taiwan Reviewed by: PLA2G6 has been certified as a causative gene in patients with autosomal recessive Yih-Ru Wu, early-onset Parkinson’s disease (EOPD). We reported an EOPD case caused by Chang Gung Memorial Hospital, Taiwan PLA2G6 gene mutation, and performed neurological examination, genetic analysis, Chin-Hsien Lin, and multimodal neuroimaging to describe this phenotype. A compound heterozygous National Taiwan University, Taiwan mutation c.991G>T/c.1472+1G>A was detected in this patient. Heterozygous for the *Correspondence: c.991G>T and c.1472+1G>A were separately detected in his parents. Pathogenicity Hsin-Yi Lai [email protected] of these two mutations were predicted according to the American college of medical Baorong Zhang genetics and genomics (ACMG) guideline. -
A Cognitive Behavioral Exposure Treatment Package for Night Terrors: a Case Study
Send Orders of Reprints at [email protected] 8 The Open Sleep Journal, 2013, 6, 8-11 Open Access A Cognitive Behavioral Exposure Treatment Package for Night Terrors: A Case Study Steven J. Linton* Center for Health and Medical Psychology, School of Law, Psychology and Social Work, Örebro University, Sweden Abstract: Night terror is a rare problem in adults characterized by nighttime episodes similar to panic attacks except that sufferers are not aware of the content. There is no current treatment, but exposure is a treatment of choice for panic. The purpose of this case study was therefore to develop and describe a novel treatment. The client had a 22-year history of night terror attacks with verbalization causing sleep difficulties and daytime fatigue. A cognitive-behavioral package featuring exposure (listening to audio recordings of the episodes) and re-conceptualization was provided over 13 sessions. Results indicated a large decrease in the ratings of the intensity of the night terror episodes. Moreover, sleep onset latency decreased while sleep quality and duration improved substantially. The client reported important increases in daytime activities and resumed working. Although caution is necessary because this is a case study, the results suggest that this technique warrants further study for people suffering from night terrors. Keywords: Night terrors, adults, exposure therapy, cognitive behavioral treatment. INTRODUCTION insomnia [7, 8] and panic disorders [9, 10]. Indeed, exposure is a treatment of choice for panic attacks and theoretical Night terrors are rare among adults, but when they do should be effective for night terrors as well [11, 12].